157 related articles for article (PubMed ID: 33908275)
1. The effects of oral anticancer parity laws on out-of-pocket spending and adherence among commercially insured patients with chronic myeloid leukemia.
Spargo A; Yost C; Squires P; Raju A; Schroader B; Brown JD
J Manag Care Spec Pharm; 2021 May; 27(5):554-564. PubMed ID: 33908275
[No Abstract] [Full Text] [Related]
2. Out-of-Pocket and Health Care Spending Changes for Patients Using Orally Administered Anticancer Therapy After Adoption of State Parity Laws.
Dusetzina SB; Huskamp HA; Winn AN; Basch E; Keating NL
JAMA Oncol; 2018 Jun; 4(6):e173598. PubMed ID: 29121177
[TBL] [Abstract][Full Text] [Related]
3. Oral Oncology Parity Laws, Medication Use, and Out-of-Pocket Spending for Patients With Blood Cancers.
Dusetzina SB; Huskamp HA; Jazowski SA; Winn AN; Wood WA; Olszewski A; Basch E; Keating NL
J Natl Cancer Inst; 2020 Oct; 112(10):1055-1062. PubMed ID: 31883008
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Anticancer Medication Use and Spending Under US Oncology Parity Laws With and Without Out-of-Pocket Spending Caps.
Dusetzina SB; Huskamp HA; Jazowski SA; Winn AN; Basch E; Keating NL
JAMA Health Forum; 2021 May; 2(5):e210673. PubMed ID: 35977314
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine Kinase Inhibitors Initiation, Cost Sharing, and Health Care Utilization in Patients with Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Claims-Based Study.
Phuar HL; Begley CE; Chan W; Krause TM
J Manag Care Spec Pharm; 2019 Oct; 25(10):1140-1150. PubMed ID: 31556823
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine Kinase Inhibitors and the Relationship With Adherence, Costs, and Health Care Utilization in Commercially Insured Patients With Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Claims-Based Study.
Phuar HL; Begley CE; Chan W; Krause TM
Am J Clin Oncol; 2020 Jul; 43(7):517-525. PubMed ID: 32304434
[TBL] [Abstract][Full Text] [Related]
7. Impact of Out-of-Pocket Pharmacy Costs on Branded Medication Adherence Among Patients with Type 2 Diabetes.
Bibeau WS; Fu H; Taylor AD; Kwan AY
J Manag Care Spec Pharm; 2016 Nov; 22(11):1338-1347. PubMed ID: 27783549
[TBL] [Abstract][Full Text] [Related]
8. Predictors of adherence to oral anticancer medications: An analysis of 2010-2018 US nationwide claims.
Vyas A; Descoteaux A; Kogut S; Parikh MA; Campbell PJ; Green A; Westrich K
J Manag Care Spec Pharm; 2022 Aug; 28(8):831-844. PubMed ID: 35876294
[No Abstract] [Full Text] [Related]
9. Association of prescription abandonment with cost share for high-cost specialty pharmacy medications.
Gleason PP; Starner CI; Gunderson BW; Schafer JA; Sarran HS
J Manag Care Pharm; 2009 Oct; 15(8):648-58. PubMed ID: 19803554
[TBL] [Abstract][Full Text] [Related]
10. Coverage and use of cancer therapies in the treatment of chronic myeloid leukemia.
Darkow T; Maclean R; Joyce GF; Goldman D; Lakdawalla DN
Am J Manag Care; 2012 Nov; 18(11 Suppl):S272-8. PubMed ID: 23327459
[TBL] [Abstract][Full Text] [Related]
11. Evaluating the relationship between quality measure adherence definitions and economic outcomes in commercial health plans: a retrospective diabetes cohort study.
Chinthammit C; Axon DR; Mollon L; Taylor AM; Pickering M; Black H; Warholak T; Campbell PJ
J Manag Care Spec Pharm; 2021 Jan; 27(1):64-72. PubMed ID: 33377445
[No Abstract] [Full Text] [Related]
12. Adherence and persistence among chronic myeloid leukemia patients during second-line tyrosine kinase inhibitor treatment.
Trivedi D; Landsman-Blumberg P; Darkow T; Smith D; McMorrow D; Mullins CD
J Manag Care Spec Pharm; 2014 Oct; 20(10):1006-15. PubMed ID: 25278323
[TBL] [Abstract][Full Text] [Related]
13. Cost sharing for antiepileptic drugs: medication utilization and health plan costs.
Joyce NR; Fishman J; Green S; Labiner DM; Wild I; Grabowski DC
Am J Manag Care; 2018 Jun; 24(6):e183-e189. PubMed ID: 29939508
[TBL] [Abstract][Full Text] [Related]
14. Patient out-of-pocket spending in cranial neurosurgery: single-institution analysis of 6569 consecutive cases and literature review.
Yoon S; Mooney MA; Bohl MA; Sheehy JP; Nakaji P; Little AS; Lawton MT
Neurosurg Focus; 2018 May; 44(5):E6. PubMed ID: 29712524
[TBL] [Abstract][Full Text] [Related]
15. Reducing out-of-pocket cost barriers to specialty drug use under Medicare Part D: addressing the problem of "too much too soon".
Doshi JA; Li P; Pettit AR; Dougherty JS; Flint A; Ladage VP
Am J Manag Care; 2017 Mar; 23(3 Suppl):S39-S45. PubMed ID: 29648739
[TBL] [Abstract][Full Text] [Related]
16. The impact of state parity laws on copayments for and adherence to oral endocrine therapy for breast cancer.
Chin AL; Bentley JP; Pollom EL
Cancer; 2019 Feb; 125(3):374-381. PubMed ID: 30566762
[TBL] [Abstract][Full Text] [Related]
17. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia.
Dusetzina SB; Winn AN; Abel GA; Huskamp HA; Keating NL
J Clin Oncol; 2014 Feb; 32(4):306-11. PubMed ID: 24366936
[TBL] [Abstract][Full Text] [Related]
18. Association of High-Deductible Health Plan Enrollment With Spending on and Use of Lenalidomide Therapy Among Commercially Insured Patients With Multiple Myeloma.
Jazowski SA; Wilson L; Dusetzina SB; Zafar SY; Zullig LL
JAMA Netw Open; 2022 Jun; 5(6):e2215720. PubMed ID: 35671056
[TBL] [Abstract][Full Text] [Related]
19. Out-of-pocket costs and oral cancer medication discontinuation in the elderly.
Kaisaeng N; Harpe SE; Carroll NV
J Manag Care Spec Pharm; 2014 Jul; 20(7):669-75. PubMed ID: 24967520
[TBL] [Abstract][Full Text] [Related]
20. Out-of-Pocket Spending for Asthma-Related Care Among Commercially Insured Patients, 2004-2016.
Sinaiko AD; Gaye M; Wu AC; Bambury E; Zhang F; Xu X; Wharam JF; Galbraith AA
J Allergy Clin Immunol Pract; 2021 Dec; 9(12):4324-4331.e7. PubMed ID: 34481128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
